Literature DB >> 25111953

Inverse effect of mucinous component on survival in stage III colorectal cancer.

Akira Ooki1, Kiwamu Akagi, Toshimasa Yatsuoka, Masako Asayama, Hiroki Hara, Gou Yamamoto, Yoji Nishimura, Kensei Yamaguchi.   

Abstract

BACKGROUND: Although mucinous adenocarcinoma (MAC) is has been recognized as a separate entity in colorectal cancer (CRC), adenocarcinoma with a mucinous component (ACM) remains poorly understood.
METHODS: The association of MAC and ACM with disease-free survival (DFS) and overall survival (OS) was examined using the Cox proportional hazard model in 425 consecutive stage III CRCs.
RESULTS: Compared with conventional adenocarcinoma (CAC), patients with MAC exhibited independently worse DFS (hazard ratio [HR], 2.64; 95% CI, 1.21-5.80; P = 0.014) and OS (HR, 3.56; 95% CI, 1.53-8.30; P = 0.003). Unexpectedly, ACM was significantly associated with worse OS than CAC (P = 0.002), despite having a similar DFS to CAC. Further, ACM patients after recurrence exhibited significantly worse OS than CAC patients (P < 0.001), similar to MAC.
CONCLUSIONS: Although ACM is similar to CAC with regard to estimated risk of recurrence, the outcome is extremely poor once recurrence occurs and is identical to MAC; one of the most aggressive phenotypes of stage III CRC. Thus, both MAC and ACM are adverse prognostic factors for OS.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  colorectal cancer; mucinous adenocarcinoma; mucinous component; stage III

Mesh:

Year:  2014        PMID: 25111953     DOI: 10.1002/jso.23742

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  6 in total

1.  Clinical significance of cellular and acellular mucin pools in rectal carcinoma following preoperative chemoradiotherapy.

Authors:  J A Cienfuegos; J Baixauli; F Rotellar; J Arredondo; J J Sola; L Arbea; C Pastor; J L Hernández-Lizoáin
Journal:  Clin Transl Oncol       Date:  2015-10-16       Impact factor: 3.405

2.  Pharmacological Targeting SHP-1-STAT3 Signaling Is a Promising Therapeutic Approach for the Treatment of Colorectal Cancer.

Authors:  Li-Ching Fan; Hao-Wei Teng; Chung-Wai Shiau; Wei-Tien Tai; Man-Hsin Hung; Shung-Haur Yang; Jeng-Kai Jiang; Kuen-Feng Chen
Journal:  Neoplasia       Date:  2015-09       Impact factor: 5.715

3.  Clinical significance of mucinous component in colorectal adenocarcinoma: a propensity score-matched study.

Authors:  Chuanwang Yan; Hui Yang; Lili Chen; Ran Liu; Wei Shang; Wenguang Yuan; Fei Yang; Qing Sun; Lijian Xia
Journal:  BMC Cancer       Date:  2021-12-01       Impact factor: 4.430

4.  Tumour infiltrating lymphocyte status is superior to histological grade, DNA mismatch repair and BRAF mutation for prognosis of colorectal adenocarcinomas with mucinous differentiation.

Authors:  David S Williams; Dmitri Mouradov; Marsali R Newman; Elham Amini; David K Nickless; Catherine G Fang; Michelle Palmieri; Anuratha Sakthianandeswaren; Shan Li; Robyn L Ward; Nicholas J Hawkins; Iain Skinner; Ian Jones; Peter Gibbs; Oliver M Sieber
Journal:  Mod Pathol       Date:  2020-02-11       Impact factor: 7.842

5.  Trends of incidence and survival in patients with gastrointestinal mucinous adenocarcinoma.

Authors:  Zhen Zong; Yonghui Luo; Houqun Ying; Anan Wang; Hui Li; Chenghao Yi
Journal:  Oncol Lett       Date:  2018-09-04       Impact factor: 2.967

6.  Identification of differentially expressed genes between mucinous adenocarcinoma and other adenocarcinoma of colorectal cancer using bioinformatics analysis.

Authors:  Xue Zhang; Jing Zuo; Long Wang; Jing Han; Li Feng; Yudong Wang; Zhisong Fan
Journal:  J Int Med Res       Date:  2020-08       Impact factor: 1.671

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.